| Literature DB >> 25104437 |
Peng Fu, Linlin Yang, Yi Sun, Li Ye, Zhiwei Cao, Kailin Tang.
Abstract
BACKGROUND: Western drugs have achieved great successes in CVDs treatment. However, they may lead to some side effects and drug resistance. On the other hand, more and more studies found that Traditional Chinese herbs have efficient therapeutic effects for CVDs, while their therapeutic mechanism is still not very clear. It may be a good view towards molecules, targets and network to decipher whether difference exists between anti-CVD western drugs and Chinese herbal ingredients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25104437 PMCID: PMC4095000 DOI: 10.1186/1471-2105-15-S4-S3
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Protein targets of herbal ingredients and western drugs in TTD.
| Class | ||||||
|---|---|---|---|---|---|---|
| number of targets | Percentage | number of targets | Percentage | number of targets | Percentage | |
| Successful targets | 81 | 39.7% | 32 | 27.1% | 84 | 9.7% |
| Clinical trial targets | 15 | 7.4% | 10 | 8.5% | 88 | 10.2% |
| Research targets | 29 | 14.2% | 32 | 27.1% | 180 | 20.9% |
| Discontinued targets | 2 | 1.7% | 3 | 2.5% | 14 | 1.6% |
| Sum of targets in TTD | 127 | 62.3% | 77 | 65.3% | 358 | 41.5% |
Drug targets related diseases from TTD.
| Type of targets | Number of diseases | d/t | |
|---|---|---|---|
| Successful target(81) | 221 | 2.73 | |
| Clinical trial target(15) | 45 | 3.0 | |
| Research target(29) | 56 | 1.93 | |
| Successful target(32) | 160 | 5.0 | |
| Clinical trial target(10) | 39 | 3.9 | |
| Research target(32) | 76 | 2.38 | |
(d/t represents the average value for the number of associated diseases for each target)
Figure 1a. the domain number of . b. Distribution of main protein biochemical family of herbal ingredients and western drugs. c. Distribution of subcellular location of targets.
Transcription factor distribution for targets of western drug and herbal ingredients
| Uniprot-id | Factor name | Num for Transcriptional genes | |
|---|---|---|---|
| P10275 | AR | 3 | |
| P05412 | c-Jun | 19 | |
| P04150 | GR-alpha | 5 | |
| P08235 | MR | 0 | |
| P10827 | T3R-alpha | 4 | |
| P10828 | T3R-beta1 | 5 | |
| P35869 | AhR | 7 | |
| Q07869 | PPAR-alpha | 0 | |
| Q03181 | PPAR-beta | 1 | |
| P51843 | DAX1 | 0 | |
| P05412 | c-Jun | 19 | |
| P03372 | ER-alpha | 8 | |
| Q04206 | RelA | 12 | |
| Q00613 | HSF1 (long/low) | 1 | |
| Q09472 | p300 | 15 | |
| P40763 | STAT3 | 3 | |
| P35869 | AhR | 7 | |
| Q07869 | PPAR-alpha | 0 | |
| Q03181 | PPAR-beta | 1 | |
| O75469 | PXR-1/SXR | 0 | |
| Q92731 | ER-beta | 1 |
(Fisher's exact test P-value, herbal ingredients: 0.00108, Western drug: 0.14684)
Figure 2The target-pathway network of .
Figure 3The target-pathway network of .
Figure 4The compound-pathway network of .
Figure 5The compound-pathway network of .
Figure 6The . The arrow near the rectangle represents the activities of compounds for the protein: up means activation, down means inhibition).
Figure 7The . The arrow near the rectangle represents the activities of compounds for the protein: up means activation, down means inhibition).
Figure 8The . The arrow near the rectangle represents the activities of drugs or herbal ingredients for the protein: up means activation, down means inhibition).